Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -38K | -50K | -28K | -30 | 0 |
| Operating Income | -6M | -6M | -5M | -4M | -4M |
| EBITDA | -8M | -5M | -4M | -3M | -4M |
| Net Income | -5M | -6M | -5M | -4M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.41
+0.00% today
1Y Change
-88.91%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Protagenic Therapeutics, Inc. (PTIX) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.41 and down 88.9% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -205.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -205.3%, free cash flow +1.8% with operating margin 0.0% and ROIC 379.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PTIX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTIX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PTIX Max Drawdown
-92.24%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PTIX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$4.5M
-27.2% YoY
Free Cash Flow
-$2.8M
-40.2% YoY
Revenue Growth
+0.0%
EPS Growth
-205.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -38K | -50K | -28K | -30 | 0 |
| Operating Income | -6M | -6M | -5M | -4M | -4M |
| EBITDA | -8M | -5M | -4M | -3M | -4M |
| Net Income | -5M | -6M | -5M | -4M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 1M | 215K | 541K |
| Total Assets | 2M | 2M | 4M | 8M | 11M |
| Total Liabilities | 7M | 943K | 655K | 1M | 1M |
| Shareholder Equity | -2M | 1M | 4M | 7M | 10M |
| Total Debt | 3M | 0 | 0 | 344K | 318K |
| Net Debt | 943K | -2M | -1M | 129K | -223K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
-40.4% YoY
Capital Expenditures
4
+100.2% YoY
Free Cash Flow
3M
-40.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
184.9%
Debt / Equity
-1.32x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.